H. Krasa

发表

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Eiji Higashihara, K. Bae, R. Gansevoort, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

J. Glockner, M. Irazabal, V. Torres, 2011, Kidney international.

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

R. Gansevoort, A. Chapman, V. Torres, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

E. J. van der Jagt, R. Gansevoort, R. Renken, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Eiji Higashihara, R. Gansevoort, A. Chapman, 2012, The New England journal of medicine.

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.

K. Swedberg, M. Gheorghiade, F. Zannad, 2013, Journal of cardiac failure.

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.

N. Olchanski, P. Cyr, T. Goss, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review

W. Winkelmayer, H. Krasa, R. Pecoits-Filho, 2019, Journal of medical economics.

Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers

H. Krasa, M. Greene, C. Burudpakdee, 2018, Current medical research and opinion.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

R. Gansevoort, A. Chapman, V. Torres, 2016, Nephrology, Dialysis and Transplantation.

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

H. Krasa, J. Ouyang, D. Oberdhan, 2022, Kidney international reports.

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.

M. Gheorghiade, H. Krasa, J. Ouyang, 2008, Journal of the American College of Cardiology.

Acute Hemodynamic Effects of Tolvaptan , a Vasopressin V 2 Receptor Blocker , in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International , Multicenter , Randomized , Placebo-Controlled Trial

M. Gheorghiade, H. Krasa, J. Ouyang, 2008 .

Thyroid Hormones Act Primarily within the Brain to Promote the Seasonal Inhibition of Luteinizing Hormone Secretion in the Ewe.

H. Krasa, C. Viguié, F. Karsch, 1999, Endocrinology.

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).

J. Verbalis, H. Krasa, J. Ouyang, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Bile Salts: Natural Detergents for the Prevention of Sexually Transmitted Diseases

D. Marcellino, H. Krasa, B. Herold, 1999, Antimicrobial Agents and Chemotherapy.

Endocrine Alterations That Underlie Endotoxin-Induced Disruption of the Follicular Phase in Ewes1

H. Krasa, V. Padmanabhan, C. Viguié, 2000, Biology of reproduction.

Endotoxin Inhibits the Reproductive Neuroendocrine Axis While Stimulating Adrenal Steroids: A Simultaneous View from Hypophyseal Portal and Peripheral Blood.

H. Krasa, C. Viguié, F. Karsch, 1997, Endocrinology.

Sub‐acute hyponatraemia more than chronic hyponatraemia is associated with serious falls and hip fractures

Connie M. Rhee, K. Kalantar-Zadeh, H. Krasa, 2019, Internal medicine journal.

Systemic Challenge with Endotoxin Stimulates Corticotropin-Releasing Hormone and Arginine Vasopressin Secretion into Hypophyseal Portal Blood: Coincidence with Gonadotropin-Releasing Hormone Suppression* * Preliminary reports have appeared in Biol Reprod [Suppl 1] 54:93, 1996, and the 1997 Program a

H. Krasa, C. Viguié, F. Karsch, 1998, Endocrinology.

Endotoxin inhibits the reproductive neuroendocrine axis while stimulating adrenal steroids: a simultaneous view from hypophyseal portal and peripheral blood.

H. Krasa, C. Viguié, F. Karsch, 1997, Endocrinology.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

P. Watkins, V. Torres, H. Krasa, 2015, Drug Safety.

Prevalence of autosomal dominant polycystic kidney disease in the European Union

H. Krasa, F. Czerwiec, J. Blais, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.

R. Hays, A. Chapman, R. Perrone, 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

K. Swedberg, M. Gheorghiade, F. Zannad, 2008, Journal of the American College of Cardiology.

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.

K. Swedberg, M. Gheorghiade, F. Zannad, 2008, JAMA.

Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease

L. Callahan, H. Krasa, D. Oberdhan, 2023, Neurology and Therapy.

Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review

W. Winkelmayer, H. Krasa, R. Pecoits-Filho, 2019, PharmacoEconomics - open.

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial

M. Gheorghiade, H. Krasa, J. Ouyang, 2007 .

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

K. Swedberg, M. Vaduganathan, M. Gheorghiade, 2012, Journal of cardiovascular medicine.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

S. Bakker, R. Gansevoort, E. Meijer, 2013, Kidney international.

Lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015, Neuropsychiatric disease and treatment.

Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Christopher Zimmer, Karl Swedberg, Faiez Zannad, 2009, European heart journal.

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data

A. Chapman, R. Perrone, H. Krasa, 2015, ClinicoEconomics and outcomes research : CEOR.

Chronic hyponatremia and association with osteoporosis among a large racially/ethnically diverse population

Connie M. Rhee, K. Kalantar-Zadeh, H. Krasa, 2019, Osteoporosis International.

OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD

A. Chapman, Berenice Y. Gitomer, R. Perrone, 2023, Kidney international reports.

Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease

M. Atkinson, R. Perrone, H. Krasa, 2023, Clinical journal of the American Society of Nephrology : CJASN.

H. Krasa, D. Oberdhan, J. Cole, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

K. Bae, A. Chapman, V. Torres, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Title Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale : A New Health-Related Quality-of-Life Instrument

R. Hays, A. Chapman, R. Perrone, 2017 .

Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

L. Callahan, H. Krasa, S. Wronski, 2020, Alzheimer's Research & Therapy.

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

H. Krasa, D. Oberdhan, A. Fernandes, 2023, BMC Nephrology.

Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Jon Neville, Eslie Dennis, Bron Kisler, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Severity of memory impairment in the elderly: Association with health care resource use and functional limitations in the United States

H. Krasa, M. Aigbogun, R. Stellhorn, 2017, Alzheimer's & dementia.

Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.

H. Krasa, F. Czerwiec, C. Orlandi, 2004, Arthritis & Rheumatism.

Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study

H. Krasa, F. Czerwiec, C. Orlandi, 2004 .

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

lack of tolerable treatment options for patients with schizophrenia

L. Citrome, H. Krasa, S. Johnston, 2015 .

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

E. J. van der Jagt, R. Gansevoort, R. Renken, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

K. Swedberg, M. Gheorghiade, F. Zannad, 2008, Journal of the American College of Cardiology.

Treatment Length of Stay for Chronic Heart Failure Patients in a Hyponatremia Registry Patients in a Hyponatremia Registry

D. Lubeck, H. Krasa, M. Danese, 2016 .

SP338ECONOMIC AND HUMANISTIC BURDEN OF DIALYSIS-DEPENDENT PATIENTS WITH CHRONIC KIDNEY DISEASE-RELATED ANEMIA: A SYSTEMATIC REVIEW

W. Winkelmayer, H. Krasa, R. Pecoits-Filho, 2018 .